Fenobam
Izgled
Fenobam | |||
---|---|---|---|
IUPAC ime |
| ||
Identifikacija | |||
CAS registarski broj | 57653-26-6 | ||
PubChem[1][2] | 162834 | ||
MeSH | |||
ChEMBL[3] | CHEMBL239800 | ||
IUPHAR ligand | 1434 | ||
Jmol-3D slike | Slika 1 | ||
| |||
| |||
Svojstva | |||
Molekulska formula | C11H11ClN4O2 | ||
Molarna masa | 266,684 | ||
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala | |||
Infobox references |
Fenobam je imidazolni derivat razvijen tokom kasnih 1970-tih kao anksiolitski lek sa svojevremeno nepoznatim molekulskim ciljem u mozgu. Naknadno, je utvrđeno da fenobam deluje potentan i selektivan negativni alosterni modulator metabotropnog glutamatnog receptora mGluR5.[4][5] On je korišten kao vodeće jedinjenje za razvoj niza novijih mGluR5 antagonista.[6][7][8][9]
Fenobam se može pripremiti u dva koraka iz kreatina.[10]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Porter RH, Jaeschke G, Spooren W et al. (November 2005). „Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity”. J. Pharmacol. Exp. Ther. 315 (2): 711–21. DOI:10.1124/jpet.105.089839. PMID 16040814.
- ↑ Marino, MJ; Conn, PJ (2006). „Glutamate-based therapeutic approaches: Allosteric modulators of metabotropic glutamate receptors”. Current opinion in pharmacology 6 (1): 98–102. DOI:10.1016/j.coph.2005.09.006. PMID 16368268.
- ↑ Wållberg, A; Nilsson, K; Osterlund, K; Peterson, A; Elg, S; Raboisson, P; Bauer, U; Hammerland, LG et al. (2006). „Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues”. Bioorganic & medicinal chemistry letters 16 (5): 1142–5. DOI:10.1016/j.bmcl.2005.11.092. PMID 16380255.
- ↑ Ceccarelli, SM; Jaeschke, G; Buettelmann, B; Huwyler, J; Kolczewski, S; Peters, JU; Prinssen, E; Porter, R et al. (2007). „Rational design, synthesis, and structure-activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure”. Bioorganic & medicinal chemistry letters 17 (5): 1302–6. DOI:10.1016/j.bmcl.2006.12.006. PMID 17189691.
- ↑ Jaeschke, G; Porter, R; Büttelmann, B; Ceccarelli, SM; Guba, W; Kuhn, B; Kolczewski, S; Huwyler, J et al. (2007). „Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists”. Bioorganic & medicinal chemistry letters 17 (5): 1307–11. DOI:10.1016/j.bmcl.2006.12.033. PMID 17196387.
- ↑ Gichinga, Moses G.; Olson, Jeremy P.; Butala, Elizabeth; Navarro, Hernán A.; Gilmour, Brian P.; Mascarella, S. Wayne; Carroll, F. Ivy (2011). „Synthesis and Evaluation of Metabotropic Glutamate Receptor Subtype 5 Antagonists Based on Fenobam”. ACS Medicinal Chemistry Letters 2 (12): 882–884. DOI:10.1021/ml200162f. PMC 3328804. PMID 22523618.
- ↑ Rasmussen, C. R.; 1976, U.S. Patent 3.983.135.